Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 426 participants.

Also called NCT03798080

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 426 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03798080
Other papers using this trial's data
  • iGlarLixi effectively reduces residual hyperglycaemia in Chinese people with type 2 diabetes on basal insulin: A post hoc analysis of the LixiLan-L-CN study Diabetes, obesity & metabolism, 2024-12 DOI, PubMed 39360440

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03798080. Randomized; no masking; primary purpose treatment. Start 2019-02-19 (actual); primary completion 2020-12-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Acronym
Lixilan-L-CN
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin glargine/Lixisenatide (HOE901/AVE0010)
Intervention (Drug)
Insulin glargine (HOE901)
Intervention (Drug)
Metformin
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03798080
Content hash
fe10bf68c64b73605bb70368a51eeb19f7a00b5bfc419f355a1e3ed6d080eba2